Insights
September 18, 2018 –
Amrita Krishnan, MD, FACP, elucidates various combination treatment approaches making use of daratumumab in the frontline setting for patients with newly diagnosed multiple myeloma.
September 18, 2018 –
Amrita Krishnan, MD, FACP, provides an overview of frontline treatment options for patients with newly diagnosed multiple myeloma, given a shift in the paradigm toward 4-drug combination strategies.
September 12, 2018 –
Amrita Krishnan, MD, FACP, shares insight on the goals and factors that affect frontline therapy selection for patients with newly diagnosed multiple myeloma and explains the potential value of minimal residual disease.
September 12, 2018 –
Amrita Krishnan, MD, FACP, reflects on the value of combination therapy approaches in multiple myeloma and considers whether they have modified transplant’s role in sequencing.
September 11, 2018 –
H. Jack West, MD, predicts how the therapeutic landscape in non–small cell lung cancer is likely to evolve based on emerging data and remarks on the potential of antiangiogenic therapy in combination with other treatment strategies in appropriate patients.
September 11, 2018 –
H. Jack West, MD, remarks on limitations in understanding the role of antiangiogenic therapy in non–small cell lung cancer and highlights preclinical data that further explore its potential in combination with other treatment strategies in various settings.
September 10, 2018 –
Susan M. O’Brien, MD, explains the potential benefits of novel combination strategies being evaluated in the frontline setting of chronic lymphocytic leukemia, as well as how treatment has and will continue to change remaining unmet needs.
September 10, 2018 –
Susan M. O’Brien, MD, reviews the clinical data supporting the use of ibrutinib as up-front therapy for patients with chronic lymphocytic leukemia and the factors to consider when sequencing therapies.
September 05, 2018 –
Sagar Lonial, MD, FACP, elucidates the treatment options available at later relapses of multiple myeloma, what unmet needs pervade throughout the disease continuum, and what future efforts might improve patient outcomes.
September 05, 2018 –
Sagar Lonial, MD, FACP, provides his perspective on the optimal selection of therapy at first progression of multiple myeloma given clinical data and the option to perform an incremental change.
